Emergent salvage surgery for massive hemoptysis after proton beam therapy for lung cancer: a case report.
Broncho-pulmonary artery fistula
Massive hemoptysis
Proton beam therapy
Salvage surgery
Journal
Surgical case reports
ISSN: 2198-7793
Titre abrégé: Surg Case Rep
Pays: Germany
ID NLM: 101662125
Informations de publication
Date de publication:
20 Apr 2021
20 Apr 2021
Historique:
received:
15
02
2021
accepted:
07
04
2021
entrez:
20
4
2021
pubmed:
21
4
2021
medline:
21
4
2021
Statut:
epublish
Résumé
Salvage surgery is an effective therapeutic option for patients experiencing relapses after chemoradiotherapy for advanced-stage lung cancer or after high-dose radiotherapy for early-stage lung cancer. We report a case involving an emergent salvage surgery for a patient with massive hemoptysis who developed lung cancer recurrence after undergoing proton beam therapy 7 years prior to presentation. A 70-year-old male patient was emergently admitted due to massive hemoptysis. He had undergone proton beam therapy for a stage I adenocarcinoma of the left upper lobe 7 years ago, and was receiving chemotherapy for local recurrence. We performed an emergent salvage pulmonary resection to achieve hemostasis. During the operation, we confirmed the presence of a left broncho-pulmonary arterial fistula, which was considered as the origin of the massive hemoptysis. We repaired the fistula between the pulmonary artery and left upper bronchus without incident; an orifice of the fistula at the left pulmonary artery was sutured using a non-absorbable monofilament, and the central portion of the orifice of the fistula at the left upper bronchus was closed with a mechanical stapling device. The postoperative diagnosis was of an adenocarcinoma-ypT3(pm1) N0M1a (dissemination)-IVA, ef1b. The patient has survived for over a year with the cancer in almost complete remission following the administration of an epidermal growth factor receptor tyrosine kinase inhibitor. Emergent salvage surgery demands high skill levels with optimal timing and correct patient selection. Our case suggested that the procedure played an important role in controlling serious bleeding and/or infectious conditions. Consequently, he could receive chemotherapy again and survive for over a year.
Sections du résumé
BACKGROUND
BACKGROUND
Salvage surgery is an effective therapeutic option for patients experiencing relapses after chemoradiotherapy for advanced-stage lung cancer or after high-dose radiotherapy for early-stage lung cancer. We report a case involving an emergent salvage surgery for a patient with massive hemoptysis who developed lung cancer recurrence after undergoing proton beam therapy 7 years prior to presentation.
CASE PRESENTATION
METHODS
A 70-year-old male patient was emergently admitted due to massive hemoptysis. He had undergone proton beam therapy for a stage I adenocarcinoma of the left upper lobe 7 years ago, and was receiving chemotherapy for local recurrence. We performed an emergent salvage pulmonary resection to achieve hemostasis. During the operation, we confirmed the presence of a left broncho-pulmonary arterial fistula, which was considered as the origin of the massive hemoptysis. We repaired the fistula between the pulmonary artery and left upper bronchus without incident; an orifice of the fistula at the left pulmonary artery was sutured using a non-absorbable monofilament, and the central portion of the orifice of the fistula at the left upper bronchus was closed with a mechanical stapling device. The postoperative diagnosis was of an adenocarcinoma-ypT3(pm1) N0M1a (dissemination)-IVA, ef1b. The patient has survived for over a year with the cancer in almost complete remission following the administration of an epidermal growth factor receptor tyrosine kinase inhibitor.
CONCLUSIONS
CONCLUSIONS
Emergent salvage surgery demands high skill levels with optimal timing and correct patient selection. Our case suggested that the procedure played an important role in controlling serious bleeding and/or infectious conditions. Consequently, he could receive chemotherapy again and survive for over a year.
Identifiants
pubmed: 33877476
doi: 10.1186/s40792-021-01177-9
pii: 10.1186/s40792-021-01177-9
pmc: PMC8058119
doi:
Types de publication
Journal Article
Langues
eng
Pagination
98Références
J Thorac Dis. 2017 Apr;9(Suppl 3):S193-S200
pubmed: 28446984
Ann Thorac Surg. 2020 Feb;109(2):e99-e101
pubmed: 31276644
Ann Thorac Surg. 2020 Oct;110(4):1123-1130
pubmed: 32473131
Ann Thorac Surg. 2019 Dec;108(6):1664-1670
pubmed: 31445048
J Cardiothorac Surg. 2018 Jan 22;13(1):13
pubmed: 29357877
J Surg Case Rep. 2015 Sep 04;2015(9):
pubmed: 26341785
Clin Lung Cancer. 2016 Sep;17(5):427-432
pubmed: 26725851
Lung Cancer. 2019 Jul;133:117-122
pubmed: 31200817
J Thorac Oncol. 2015 Nov;10(11):1616-24
pubmed: 26317918
Radiother Oncol. 2010 Apr;95(1):32-40
pubmed: 19733410
J Thorac Cardiovasc Surg. 2017 Aug;154(2):689-699
pubmed: 28495066
Lung Cancer. 2020 Jul;145:105-110
pubmed: 32422344
Jpn J Radiol. 2015 Jun;33(6):370-4
pubmed: 25900415